argenex (NASDAQ:ARGX) Stock Price Expected to Rise, HC Wainwright Analyst Says

argenex (NASDAQ:ARGX) had its price target lifted by research analysts at HC Wainwright from $915.00 to $940.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 22.57% from the company’s current price.

Other equities research analysts also recently issued reports about the company. Evercore upped their price objective on argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. DZ Bank upgraded argenex to a “strong-buy” rating in a report on Friday, December 19th. Citigroup lowered their price target on argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. Piper Sandler boosted their price objective on shares of argenex from $820.00 to $930.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $999.22.

argenex Stock Down 0.6%

ARGX stock opened at $766.92 on Friday. argenex has a 52 week low of $510.05 and a 52 week high of $934.62. The firm has a market capitalization of $47.46 billion, a P/E ratio of 39.29, a price-to-earnings-growth ratio of 0.67 and a beta of 0.37. The company has a fifty day simple moving average of $826.36 and a two-hundred day simple moving average of $811.97.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 63.59%. The firm had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. As a group, analysts anticipate that argenex will post 3.13 EPS for the current year.

Institutional Trading of argenex

Institutional investors and hedge funds have recently made changes to their positions in the business. Abound Wealth Management grew its holdings in shares of argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after purchasing an additional 32 shares during the last quarter. Sound Income Strategies LLC bought a new stake in argenex during the 4th quarter valued at about $28,000. Ameriflex Group Inc. purchased a new stake in argenex in the 3rd quarter valued at about $32,000. Aventura Private Wealth LLC bought a new position in argenex in the 4th quarter worth about $38,000. Finally, Sunbelt Securities Inc. bought a new position in argenex in the 3rd quarter worth about $36,000. 60.32% of the stock is currently owned by institutional investors.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.